Exenatide Linked to Less Hyperglycemia After Stroke
A phase 2, international, multicenter, randomized controlled TEXAIS trial enrolled 350 patients following an ischemic stroke. Within 9 hours of stroke onset, patients received either standard care or a subcutaneous injection of 5 mg of exenatide twice daily for 5 days. On admission, 42% of patients had hyperglycemia, defined as blood glucose > 7.0 mmol/L.

The study's primary outcome was at least an 8-point improvement in National Institutes of Health Stroke Scale (NIHSS) score by 7 days after treatment with exenatide. Although there was a trend toward better scores with exenatide, the score was not significantly different between groups (56.7% with standard care vs 61.2% with exenatide; adjusted odds ratio, 1.22; P = .38). However, when the researchers examined hyperglycemia frequency, they found significantly lower incidence in patients treated with exenatide (P = .002).

Treatment with the diabetes drug exenatide was associated with a significant decrease in hyperglycemia in acute stroke patients. The research could offer clinicians an alternative to insulin therapy to treat hyperglycemia and reduce glucose levels, which are elevated in up to 60% of stroke patients and associated with worse outcomes after stroke.

Source: https://www.medscape.com/viewarticle/973840?src=rss#vp_1